Eli Lilly &Co. in conjunction with Amylin Pharmaceuticals Inc. revealed this week that a new clinical study proves their new diabetes drug is just as effective as insulin, but doesn’t lead to weight gain. Weight gain and obesity are two of the foremost concerns for diabetics .
The study tested the drug, called exenatide, amongst type 2 diabetes patients. 18 per cent of those surveyed reached IDF (International Diabetes Federation) recommended levels. This compares to just 9 per cent taking the Novo Nordisk drug NovoMix.
The patients who took exenatide also lost an average of 5.5 pounds after just a year of treatment. Those within the insulin group gained an average of 6.4 pounds.
Exenatide has passed a critical stage in its acceptance. It was granted FDA approval last April. Last year, Eli Lilly submitted a marketing application to European regulators. Exenatide is known as an incretin mimetic –a new type of compound that mimics the glucose lowering hormones naturally produced by the body.
Pharmaceutical and biotechnology firms are racing to gain and maintain shares in the emerging global diabetes market. When a blockbuster drug can make multi-millions for a company, it is no surprise. Hopefully, this diverse competition will lead to better diabetes treatment in the near future.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…